Clara Rodríguez Fernández, Author at Labiotech.eu - Page 38 of 63

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

biodesign challenge 2017 winner

News and Trends 1 Jul 2017

Quantum Worms from London win the Biodesign Challenge 2017

A team of students from Central Saint Martins, London, has won this year’s biodesign challenge with a project in which worms turn into tech factories. Every year, teams working at the intersection of biology and design compete to win the Biodesign Challenge held at the famous New York City’s Museum of Modern Art (MoMA). This year’s edition […]

July 1, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

etherna melanoma mrna therapy

News and Trends 30 Jun 2017

Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma

eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy based on off-the-shelf mRNA technology. eTheRNA is one of the few companies working in mRNA therapies that are running clinical trials. The Belgian biotech has announced the start of a Phase Ib trial with its candidate TriMix-MEL, also called ECI-006, in patients […]

June 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

nightstarx blindness gene therapy

News and Trends 30 Jun 2017

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the market, the company has closed a Series C round with $45M (€39.5M) […]

June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

servier transgene car t cells viral vector

News and Trends 29 Jun 2017

Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology

Transgene will help Servier develop new methods based on viral vectors to improve the precision of genetic modifications and the production of CAR-T cells. The French pharma Servier decided to enter the promising CAR-T field in 2015, when it acquired the rights to UCART19 from Cellectis. The therapy, currently in Phase I, has already saved two babies […]

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

genkyotex liver fibrosis nox phase ii

News and Trends 29 Jun 2017

This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis

Genkyotex has announced a new Phase II trial in diabetic kidney disease and patient enrolment in another Phase II study for PBC. Genkyotex is not giving up after its lead candidate, GKT831, failed to meet the primary endpoint in a Phase II trial in patients with type 2 diabetes and kidney disease. The French biotech has […]

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Basel University Muscular Dystrophy

News and Trends 28 Jun 2017

Swiss Scientists Have Designed New Proteins to Treat Muscular Dystrophy

Researchers at the University of Basel have designed two proteins that can reverse congenital muscular dystrophy and increase the lifespan of mice. Congenital muscular dystrophy (CMD) englobes several genetic diseases that cause muscle weakness from birth. As patients age, the disease becomes more severe and affects breathing, often leading to death before adulthood. Unfortunately, there […]

June 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

Kerecis fish skin wound healing

News and Trends 28 Jun 2017

A Peek into the Icelandic Company using Fish Skin to Heal Wounds

Kerecis exploits the natural properties of fish skin to manufacture wound dressings that help tissues repair much faster than before. From a small town in northern Iceland, Kerecis is revolutionizing the treatment of wounds with a local product, fish. The company has developed a method to turn their skin into wound dressings that promote cell growth […]

June 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

bavarian nordic rsv vaccine common cold

News and Trends 28 Jun 2017

Danish Biotech Reports Positive Phase II data for a Common Cold Vaccine

Bavarian Nordic has announced positive Phase II results for its universal vaccine against the common cold virus, RSV, which can be deadly for the elderly. The respiratory syncytial virus (RSV) is one of the perpetrators behind the common cold. For most, the virus just leads to a few uncomfortable days or weeks. But for children […]

June 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 434566348

News and Trends 28 Jun 2017

UPDATE: The First Off-the-Shelf CAR-T Cancer Therapy has Entered the Clinic

Update (28/06/2017): Cellectis has announced the first administration of UCART123 in its Phase I trial in Acute Myeloid Leukemia. Update (07/02/2017): the FDA has granted Cellectis IND approval to start clinical trials with UCART123. Original publication 04/01/2017 Cellectis is preparing to start the first clinical trial ever using an allogeneic CAR-T therapy that could reduce […]

June 28, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Araclon Biotech Alzheimers Vaccine Spain Zaragoza

News and Trends 27 Jun 2017

A Spanish Vaccine to fight Alzheimer’s Before Symptoms Appear enters Phase II

Araclon Biotech will advance to Phase II with an Alzheimer’s vaccine that could succeed where many others have failed before. Araclon Biotech, in Zaragoza, Spain, has announced today the approval from the Spanish Agency of Medicines and Medical Devices to start a Phase II trial testing its Alzheimer’s vaccine in 120 patients in 22 centers across Europe. The […]

June 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

apheabio microorganism biopesticides biostimulants

News and Trends 26 Jun 2017

New Belgian Biotech will use Microorganisms to Replace Pesticides and Fertilizers

Aphea.Bio has gathered a total of €9M in funding to start working on a new technology to produce biopesticides and biostimulants for European agriculture. Belgium has a new biotech that will be dedicated to developing sustainable, microorganism-based biopesticides and biostimulants. Aphea.Bio has raised €7.7M in a Series A round led by the Belgian life sciences investor V-Bio Ventures in addition to a €1.3M grant […]

June 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández

type 1 diabetes insulin therapy uppsala university hospital

News and Trends 23 Jun 2017

Diabetic Patients that Still Produce Insulin might be the Key to a New Therapy

A study from Uppsala University has identified higher levels of interleukin-35 in type 1 diabetics that still produce insulin years after their diagnosis. Researchers at Uppsala University have published the first study in humans that shows the potential of interleukin-35 (IL-35) as a promising new target to treat type 1 diabetes. The results, published in […]

June 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT